MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study

Jahr

2014

Autoren

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Ziemssen T, Duda P; RESTORE.

Verlag

Neurology. 2014 Apr 29;82(17):1491-8.

Link

https://doi.org/10.1212/wnl.0000000000000355

MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study

Data on Ocrelizumab Treatment Collected by MS Patients in Germany Using Brisa App

Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland

Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab

Sensitive Identification of Asymmetries and Neuromuscular Deficits in Lower Limb Function in Early Multiple Sclerosis

Neurofilaments as biomarkers in neurological disorders — towards clinical application